TearLab Corp (TEAR) Given Consensus Recommendation of “Buy” by Brokerages
Shares of TearLab Corp (NASDAQ:TEAR) have earned an average recommendation of “Buy” from the six research firms that are covering the stock. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $5.75.
TEAR has been the subject of several recent research reports. Rodman & Renshaw reaffirmed a “buy” rating and set a $12.00 price objective on shares of TearLab Corp in a research report on Friday, March 10th. Zacks Investment Research raised TearLab Corp from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a research report on Thursday, May 11th. Feltl & Co. cut TearLab Corp from a “strong-buy” rating to a “buy” rating and set a $9.00 price objective for the company. in a research report on Saturday, March 11th. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of TearLab Corp in a research report on Tuesday, May 16th. Finally, Craig Hallum set a $6.00 price objective on TearLab Corp and gave the stock a “buy” rating in a research report on Saturday, March 11th.
TearLab Corp (NASDAQ:TEAR) traded down 0.49% during midday trading on Friday, hitting $2.04. The stock had a trading volume of 153,258 shares. The stock has a 50-day moving average of $2.21 and a 200-day moving average of $4.28. TearLab Corp has a 52 week low of $1.85 and a 52 week high of $9.00. The firm’s market cap is $10.95 million.
TearLab Corp (NASDAQ:TEAR) last posted its quarterly earnings data on Monday, May 15th. The medical research company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by $0.07. The firm had revenue of $6.70 million during the quarter, compared to the consensus estimate of $7.02 million. TearLab Corp’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.21) earnings per share. Analysts forecast that TearLab Corp will post ($2.82) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/05/26/tearlab-corp-tear-given-consensus-recommendation-of-buy-by-brokerages.html.
In related news, major shareholder Awm Investment Company, Inc. sold 327,674 shares of the company’s stock in a transaction dated Thursday, March 30th. The stock was sold at an average price of $3.20, for a total transaction of $1,048,556.80. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 11.60% of the company’s stock.
An institutional investor recently raised its position in TearLab Corp stock. AWM Investment Company Inc. increased its stake in TearLab Corp (NASDAQ:TEAR) by 37.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,277,250 shares of the medical research company’s stock after buying an additional 2,000,000 shares during the period. AWM Investment Company Inc. owned approximately 13.76% of TearLab Corp worth $4,730,000 as of its most recent SEC filing. 36.09% of the stock is owned by institutional investors.
TearLab Corp Company Profile
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.
Receive News & Ratings for TearLab Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corp and related companies with MarketBeat.com's FREE daily email newsletter.